Susan Harris

1.0k total citations
25 papers, 778 citations indexed

About

Susan Harris is a scholar working on Dermatology, Endocrinology, Diabetes and Metabolism and Molecular Biology. According to data from OpenAlex, Susan Harris has authored 25 papers receiving a total of 778 indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Dermatology, 7 papers in Endocrinology, Diabetes and Metabolism and 6 papers in Molecular Biology. Recurrent topics in Susan Harris's work include Psoriasis: Treatment and Pathogenesis (6 papers), Acne and Rosacea Treatments and Effects (5 papers) and Dermatology and Skin Diseases (4 papers). Susan Harris is often cited by papers focused on Psoriasis: Treatment and Pathogenesis (6 papers), Acne and Rosacea Treatments and Effects (5 papers) and Dermatology and Skin Diseases (4 papers). Susan Harris collaborates with scholars based in United States, United Kingdom and Canada. Susan Harris's co-authors include Robert Frederich, Robert Wolf, Niklas Berglind, Mark Donovan, Roland Chen, Fred T. Fiedorek, Kenneth W. Mahaffey, John H. Alexander, William Hollingworth and James Brennan and has published in prestigious journals such as Circulation, Journal of Clinical Oncology and The American Journal of Cardiology.

In The Last Decade

Susan Harris

24 papers receiving 749 citations

Peers

Susan Harris
Jan Stratmann Germany
Andrea Repaci Italy
V. Kerlan France
Greg Anglin United States
Kalyane Bach‐Ngohou France
Alessandro Scoppola Italy
Leslie A. Garrett United States
Yuanshan Cui China
William L. Bailey United States
Jawaid Younus Canada
Jan Stratmann Germany
Susan Harris
Citations per year, relative to Susan Harris Susan Harris (= 1×) peers Jan Stratmann

Countries citing papers authored by Susan Harris

Since Specialization
Citations

This map shows the geographic impact of Susan Harris's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Susan Harris with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Susan Harris more than expected).

Fields of papers citing papers by Susan Harris

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Susan Harris. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Susan Harris. The network helps show where Susan Harris may publish in the future.

Co-authorship network of co-authors of Susan Harris

This figure shows the co-authorship network connecting the top 25 collaborators of Susan Harris. A scholar is included among the top collaborators of Susan Harris based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Susan Harris. Susan Harris is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Glick, Brad, et al.. (2021). Once-Daily Halobetasol Propionate 0.01% Lotion for Moderate-to-Severe Plaque Psoriasis: Phase 3 Analysis of Hispanic Participants. Journal of Drugs in Dermatology. 20(3). 252–258. 2 indexed citations
2.
Lebwohl, Mark, Linda Stein Gold, Kim Papp, et al.. (2021). Long‐term safety and efficacy of a fixed‐combination halobetasol propionate 0.01%/tazarotene 0.045% lotion in moderate‐to‐severe plaque psoriasis: phase 3 open‐label study. Journal of the European Academy of Dermatology and Venereology. 35(5). 1152–1160. 12 indexed citations
3.
Eichenfield, Lawrence F., Jeremy Sugarman, Eric Guenin, Susan Harris, & Varsha Bhatt. (2019). Novel tretinoin 0.05% lotion for the once‐daily treatment of moderate‐to‐severe acne vulgaris in a preadolescent population. Pediatric Dermatology. 36(2). 193–199. 12 indexed citations
4.
Tanghetti, Emil, Leon Kircik, Lawrence J. Green, et al.. (2019). A Phase 2, Multicenter, Double-Blind, Randomized, Vehicle-Controlled Clinical Study to Compare the Safety and Efficacy of a Novel Tazarotene 0.045% Lotion and Tazarotene 0.1% Cream in the Treatment of Moderate-to-Severe Acne Vulgaris. PubMed. 18(6). 542–542. 20 indexed citations
5.
Kircik, Leon, et al.. (2019). Assessing the Synergistic Effect of a Fixed Combination Halobetasol Propionate 0.01% and Tazarotene 0.045% Lotion in Moderate-to-Severe Plaque Psoriasis. PubMed. 18(3). 279–284.. 3 indexed citations
6.
Kircik, Leon, Hilary Baldwin, Edward Lain, et al.. (2019). Novel Tretinoin 0.05% Lotion for the Once-daily Treatment of Moderate-to-Severe Acne Vulgaris in an Adult and Adolescent Female Population. PubMed. 18(2). 178–188. 5 indexed citations
7.
Bhatia, Neal, David M. Pariser, Leon Kircik, et al.. (2018). Safety and Efficacy of a Halobetasol 0.01%/Tazarotene 0.045% Fixed Combination Lotion in the Treatment of Moderate-to-severe Plaque Psoriasis: A Comparison with Halobetasol Propionate 0.05% Cream.. PubMed. 11(11). 15–19. 2 indexed citations
8.
Lebwohl, Mark, Kim Papp, Lauren B. Marangell, et al.. (2017). Psychiatric adverse events during treatment with brodalumab: Analysis of psoriasis clinical trials. Journal of the American Academy of Dermatology. 78(1). 81–89.e5. 124 indexed citations
9.
Harris, Susan, et al.. (2016). Patient education in clinical trials and throughout the product lifecycle. Medical Writing. 25. 23–30.
10.
Biddle, Lucy, Sangeetha Paramasivan, Susan Harris, et al.. (2016). Patients' and clinicians' experiences of holistic needs assessment using a cancer distress thermometer and problem list: A qualitative study. European Journal of Oncology Nursing. 23. 59–65. 37 indexed citations
11.
Hollingworth, William, Chris Metcalfe, Susan Harris, et al.. (2013). Are Needs Assessments Cost Effective in Reducing Distress Among Patients With Cancer? A Randomized Controlled Trial Using the Distress Thermometer and Problem List. Journal of Clinical Oncology. 31(29). 3631–3638. 90 indexed citations
12.
13.
Frederich, Robert, John H. Alexander, Fred T. Fiedorek, et al.. (2010). A Systematic Assessment of Cardiovascular Outcomes in the Saxagliptin Drug Development Program for Type 2 Diabetes. Postgraduate Medicine. 122(3). 16–27. 182 indexed citations
14.
Frederich, Robert, Mark Donovan, Niklas Berglind, et al.. (2009). Abstract 978: Cardiovascular Safety of Saxagliptin as Mono- or Add-on Therapy in Patients With Type 2 Diabetes. Circulation. 120. 2 indexed citations
15.
Harris, Susan, John A. Scott, Jeffrey L. Brown, Peter Charlton, & Prakash Mistry. (2005). Preclinical anti-tumor activity of XR5944 in combination with carboplatin or doxorubicin in non-small-cell lung carcinoma. Anti-Cancer Drugs. 16(9). 945–951. 12 indexed citations
16.
Harris, Susan, et al.. (2005). Antitumour activity of XR5944 in vitro and in vivo in combination with 5-fluorouracil and irinotecan in colon cancer cell lines. British Journal of Cancer. 92(4). 722–728. 29 indexed citations
17.
White, WB, et al.. (2001). A forced titration study of antihypertensive efficacy of candesartan cilexetil in comparison to losartan: CLAIM Study II. Journal of Human Hypertension. 15(7). 475–480. 42 indexed citations
18.
Kloner, Robert A., Myron H. Weinberger, James L. Pool, et al.. (2001). Comparative effects of candesartan cilexetil and amlodipine in patients with mild systemic hypertension. The American Journal of Cardiology. 87(6). 727–731. 55 indexed citations
19.
Harris, Susan. (2000). Establishing an intrauterine insemination programme from a nursing perspective. Human Fertility. 3(2). 121–123. 2 indexed citations
20.
Neutel, Joel M., Matthew R. Weir, Marvin Moser, et al.. (2000). The Effects of Candesartan Cilexetil in Isolated Systolic Hypertension: A Clinical Experience Trial.. PubMed. 2(3). 181–186. 9 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Jan Stratmann Breakdown of academic impact, for papers by Andrea Repaci Breakdown of academic impact, for papers by V. Kerlan Breakdown of academic impact, for papers by Greg Anglin Breakdown of academic impact, for papers by Kalyane Bach‐Ngohou Breakdown of academic impact, for papers by Alessandro Scoppola Breakdown of academic impact, for papers by Leslie A. Garrett Breakdown of academic impact, for papers by Yuanshan Cui Breakdown of academic impact, for papers by William L. Bailey Breakdown of academic impact, for papers by Jawaid Younus
Rankless by CCL
2026